DBV Technologies (DBVT) Cash from Operations Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 85.14% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 74.39% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.23% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 158.60% |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | -149.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -149.24% |
| Dec 31, 2025 | -187.08% |
| Sep 30, 2025 | -44.43% |
| Jun 30, 2025 | 3.42% |
| Mar 31, 2025 | 43.21% |
| Dec 31, 2024 | 10.48% |
| Sep 30, 2024 | -14.73% |
| Jun 30, 2024 | -37.26% |
| Mar 31, 2024 | -66.46% |
| Dec 31, 2023 | 42.70% |
| Sep 30, 2023 | 2.37% |
| Jun 30, 2023 | -149.30% |
| Mar 31, 2023 | -1,305.33% |
| Dec 31, 2022 | -27.12% |
| Sep 30, 2022 | 12.64% |
| Jun 30, 2022 | 66.17% |
| Mar 31, 2022 | 95.90% |
| Dec 31, 2021 | 43.96% |
| Sep 30, 2021 | 45.65% |
| Jun 30, 2021 | 24.56% |
| Mar 31, 2021 | 27.13% |
| Dec 31, 2020 | -153.23% |
| Sep 30, 2020 | 64.95% |
| Jun 30, 2020 | 53.68% |
| Dec 31, 2019 | 140.40% |
| Sep 30, 2019 | 2.38% |
| Jun 30, 2019 | -11.49% |
| Dec 31, 2018 | -15.86% |
| Dec 31, 2017 | -109.38% |
| Dec 31, 2016 | -371.41% |
| Dec 31, 2015 | -4.21% |